<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03879876</url>
  </required_header>
  <id_info>
    <org_study_id>P150949J</org_study_id>
    <secondary_id>2018-001029-14</secondary_id>
    <nct_id>NCT03879876</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Human T Lymphoid Progenitor (HTLP) Injection After Partially HLA Compatible Allogeneic Hematopoietic Stem Cell Transplantation in SCID Patients</brief_title>
  <acronym>HTLP Necker</acronym>
  <official_title>A Phase I/II Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Partially HLA Compatible Allogeneic Hematopoietic Stem Cell Transplantation in SCID Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and the efficacy of Human T Lymphoid
      Progenitor (HTLP) injection to accelerate immune reconstitution after partially HLA
      compatible allogeneic hematopoietic stem cell transplantation in SCID patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Not provided
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 13, 2020</start_date>
  <completion_date type="Anticipated">June 3, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 3, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity (DLT)</measure>
    <time_frame>3 months post-transplant</time_frame>
    <description>to evaluate the procedure safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>reconstitution of the CD3+ TCRαβ+ cell compartment</measure>
    <time_frame>Month 3</time_frame>
    <description>determined by the presence of ≥ 300/µL total, circulating CD3+ TCRαβ+ T cells to evaluate the efficacy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time course of reconstitution of the different T cell subpopulations</measure>
    <time_frame>Month 3, month 6, month 12</time_frame>
    <description>time necessary to reach a normal number of naïve CD4+ and CD8+ T cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of recent thymic emigrants</measure>
    <time_frame>Month 3, month 6, month 12</time_frame>
    <description>To evaluate the active thymopoiesis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-cell receptor excision circles (TREC ) number in peripheral blood</measure>
    <time_frame>Month 3, month 6, month 12</time_frame>
    <description>To evaluate the active thymopoiesis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TCR rearrangements</measure>
    <time_frame>Month 3, month 6, month 12</time_frame>
    <description>By NGS analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-cell reconstitution</measure>
    <time_frame>Month 6, month 12</time_frame>
    <description>number and phenotype for naïve IgD+CD27-, marginal zone IgD+CD27+, switched memory IgD-CD27+, and IgD-CD27- cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin (Ig) levels</measure>
    <time_frame>Month 6, month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NK cell numbers</measure>
    <time_frame>Month 6, month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of infections</measure>
    <time_frame>12 months post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of acute and chronic episodes of graft versus host disease (GVHD)</measure>
    <time_frame>24 months post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years post-transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Pediatric Patients</condition>
  <condition>Any Type of Severe Combined Immunodeficiency (SCID)</condition>
  <condition>Partial HLA Incompatible Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)</condition>
  <arm_group>
    <arm_group_label>Human T Lymphoid Progenitor (HTLP) injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human T Lymphoid Progenitor cells (HTLPs) obtained after a brief period of ex vivo culture in the presence of the fusion protein DL-4, Retronectin® and a combination of cytokines</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Human T Lymphoid Progenitor (HTLP) injection</intervention_name>
    <description>Injection of progenitors derived from HTLP culture at Day 8-Day 12 after partially HLA compatible allogeneic hematopoietic stem cell transplantation in SCID patients (Day7 of culture)</description>
    <arm_group_label>Human T Lymphoid Progenitor (HTLP) injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pediatric patients affected by any type of SCID confirmed by clinical, immunological
             and/or molecular diagnosis and eligible for an allogeneic HSCT

          -  Absence of a matched sibling donor or a matched unrelated donor (MUD) 10/10

          -  Clinical conditions incompatible with the search of a MUD

          -  Written, informed consent of parents/ legal representative (child)

          -  Age ≤ 2 years at the time of screening

          -  No prior therapy with allogeneic stem cell transplantation

          -  No treatment with another investigational drug within one month before inclusion

          -  Patient affiliated to social security

        Exclusion Criteria:

          -  Presence of an HLA genoidentical donor

          -  Absence of written parental consent

          -  Treatment with another investigational drug within one month before inclusion

          -  Positive for HIV infection by genome PCR

          -  Contra-indication to allogeneic transplantation or conditioning therapy (except SCID
             patients with DNA repair deficiency)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle ANDRE, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institut National de la Santé Et de la Recherche Médicale, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Despina MOSHOUS, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris and Université Paris Descartes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marina CAVAZZANA, MD &amp; PhD</last_name>
    <phone>+33 1 44 49 50 68</phone>
    <email>m.cavazzana@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valérie JOLAINE, manager</last_name>
    <phone>+33 1 42 19 28 79</phone>
    <email>valerie.jolaine@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Unité d'Immunologie Hématologie Rhumatologie Pédiatrique (UIHR),</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina CAVAZZANA, MD, PhD</last_name>
      <phone>33 1 44 49 50 68</phone>
      <email>m.cavazzana@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 15, 2019</study_first_submitted>
  <study_first_submitted_qc>March 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SCID</keyword>
  <keyword>hematopoietic stem cell transplantation</keyword>
  <keyword>Human T Lymphoid Progenitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Severe Combined Immunodeficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

